Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats

European Journal of Pharmacology

Volumn 626, Issue 2-3, 2010, Pages 262-265

  Veeresh Babu, S V ^a   Veeresh, B ^a   Patil, Anup A ^a   Warke, Y B ^a  

^a Karnatak Lingayat Education Society   (India)

Author keywords

Benign prostatic hyperplasia; Lauric acid; Myristic acid; Testosterone

Indexed keywords

FINAST; FINASTERIDE; LAURIC ACID; MYRISTIC ACID; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; WEIGHT CHANGE;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; LAURIC ACIDS; MALE; MYRISTIC ACID; ORGAN SIZE; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; TESTOSTERONE;

EID: 70649101234     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.037     Document Type: Article

References (19)

1. Aliaev Iu.G., Vinarov A.Z., Lokshin K.L., and Spivak L.G. Five-year experience in treating patients with permixon (Serenoa repens "Pierre Fabre Medicament") [Russian]. Urologia 1 (2002) 23-25
2. Arruzabala M.L., Molina V., Mas R., Carbajal D., Marrero D., Gonzalez V., and Rodriguez E. Effect of coconut oil on testosterone-induced prostatic hyperplasia in Sprague-Dawley rats. J. Pharm. Pharmacol. 59 (2006) 995-999
3. Barry M.J. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urol. 58 (2001) 20-32
4. Bartsch G., Rittmaster R.S., and Klocker H. Dihydrotestosterone and 5-alpha reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 37 (2000) 367-380
5. Carbajal D., Molina V., Mas R., and Arruzazabala M.L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruit, on prostate hyperplasia induced in rats. Curr. Ther. Res. 65 (2005) 505-514
6. Carson C., and Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 suppl 1 (2003) 2-7
7. Geller J. Benign prostatic hyperplasia: pathogenesis and medical therapy. J. Am. Geriatr. Soc. 39 (1991) 1208-1216
8. Gossel T.A., and Wuest J.R. New drugs of 2004 for treatment of benign prostatic hyperplasia: Avodart and Uroxatal. Continuing education for Pharmacist 22 2 (2004) 1-4. http://www.nodakpharmacy.net www.nodakpharmacy.net
9. Liang T., and Liao S. Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochem. J. 285 (1992) 557-562
10. Lowe F.C., Dreikorn K., Borkowski A., Braeckman J., Denis L., Ferrari P., Gerber G., Levin R., Perrin P., and Senge T. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37 (1998) 187-193
11. McCollen J.D., Wilson J.D., George F.W., Geller J., Pappas F., and Stoner E. Finasteride an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 74 (1992) 505-508
12. Michel M.C., Taguchi K., Schafers R.S., Schafers R.S., Williams T.J., Clarke D.E., and Ford A.P. α1-adrenoceptors subtype in humans cardiovascular and urogenital system. Adv. Pharmacol. 42 (1998) 394-398
13. Niederprum H.J., Schweikert H.U., and Zanker K.S. Testosterone 5 alpha-reductase inhibition by free fatty acids from Sabal serrulata fruit. Phytomedicine 1 (1994) 127-133
14. Patel A.K., and Chapple C.R. Benign prostatic hyperplasia: treatment in primary health care. BMJ 333 (2008) 535-539
15. Plosker G.L., and Brogden R.N. Serenoa repens (Permixon). A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drug Aging 9 (1996) 379-395
16. Raynaud J.P., Cousse H., and Martin P.M. Inhibition of type 1 and 2 5-alpha reductase activity by free fatty acids, active ingredients of Permixon. J. Steroid Biochem. Mol. Biol. 82 (2002) 233-239
17. Slaa E., Francisca E.A.E., and Hendricks J.C.M. Quality of life assessment in patients after laser prostatectomy. Br. J. Urol. 80 (1997) 211-216
18. Weisser H., Tunn S., Behnke B., and Krieg M. Effect of the Sabal serrulata extract IDS 89 and its subfractions on 5-alpha reductase activity in human prostatic hyperplasia. Prostate. 28 (1996) 300-306
19. Wilt T., Ishani A., MacDonald R., Muhow C., and Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 3 CD001423 (2000)